BioSpace News Archive

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs reported financial results for its fiscal first quarter 2021, for the three month period ending September 30, 2020.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35 th Society for Immunotherapy of Cancer (SITC) virtual annual meeting. HPN601 is the first conditionally active T cell engager program from Harpoon. It targets the tumor antigen epithelial cell adhesion molecule (EpCAM) and is based

On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020 Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndrome

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. As previously reported, the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, change fr

Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtual investor conferences.

Revenue increased 34% versus prior year Avenova ® unit sales set quarterly record Exited Q3 with $13.4 million in cash and equivalents Regained compliance with NYSE American continued-listing standards Launches CelleRx ® Clinical Reset™ into beauty market Conference call begins at 4:30 p.m. Eastern time today EMERYVILLE, Calif.--( BUSINESS WIRE )-- NovaBay ® Pharmaceuticals, Inc . (NYSE American:

Successfully raised $96 million in Series B financing and completed $181 million IPO Established management team with successful track record of developing and commercializing AAV9-based gene therapies for monogenic diseases of the central nervous system Company on track to initiate a Phase 1/2 clinical trial of TSHA-101 in GM2 gangliosidosis by the end of 2020 and plans to submit four INDs in 2021

Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of energy-based aesthetic systems for practitioners worldwide, today announced that it will participate in two virtual fireside chats at the following investor conferences in November. Conference: Stifel Virtual Healthcare Conference Date: Tuesday, November 17, 2020 Fireside Chat: 3:20 p.m. ET Speakers: Dave Mowry, Chief Executive O